Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP7 | Q93009 | 1/20 | 0.35 |
| ▸ | MET | P08581 | 8/20 | 0.35 |
| ▸ | KDR | P35968 | 2/20 | 0.35 |
| ▸ | CA1 | P00915 | 2/20 | 0.33 |
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
| ▸ | CA4 | P22748 | 2/20 | 0.33 |
| ▸ | CA9 | Q16790 | 2/20 | 0.33 |
| ▸ | REN | P00797 | 2/20 | 0.33 |
| ▸ | PARP1 | P09874 | 1/20 | 0.32 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.31 |
| ▸ | LCK | P06239 | 1/20 | 0.31 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.31 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4281139 | 0.81 | MET (0.36) | USP7METKDRUTS2R | |
| SCHEMBL4286189 | 0.77 | KMT2A (0.47) | CA1CA2CA4CA9 | |
| SCHEMBL4284051 | 0.77 | CA1 (0.34) | CA1CA2CA4CA9REN | |
| SCHEMBL4294380 | 0.74 | S1PR4 (0.38) | CA1CA2CA4CA9REN | |
| SCHEMBL3493396 | 0.73 | TEAD1 (0.46) | CA1CA2CA4CA9REN | |
| SCHEMBL4290889 | 0.73 | KDM4E (0.43) | CA1CA2CA4CA9REN | |
| Hydrochloric Acid SCHEMBL4285513 | 0.72 | MEN1 (0.43) | — | |
| Hydrochloric Acid SCHEMBL4749978 | 0.72 | MEN1 (0.43) | — | |
| Hydrochloric Acid SCHEMBL4289621 | 0.72 | LMNA (0.48) | — | |
| Hydrochloric Acid SCHEMBL4290963 | 0.72 | KDM4E (0.43) | REN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227560-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-09-10 | — | — | US | disclosed |
| US-20090156612-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156612-A1 | Substituted imidazole compound and use thereof | REN, ACE, AGT | USP7 2123/4885MET 408/4885KDR 1092/4885 |
| US-20090227560-A1 | Substituted imidazole compound and use thereof | REN, ACE, AGT | USP7 2123/4885MET 408/4885KDR 1092/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.